Hence, inhibiting the STAT3 signaling pathway may reverse resistance in breast cancer, and offer a novel strategy for managing resistant tumors (Kettner et al., 2019; Huang et al., 2018). This evidence concerns the gene STAT3 and breast carcinoma.